Key Takeaways
- •Revenue growth: Increased orders for peptide manufacturing translate directly into higher cash inflows, but timing depends on contract milestones and payment terms.
- •Receivables management: Bachem often invoices after delivering batches. Longer payment cycles from large pharma clients can tie up cash, reducing CFO.
- •Inventory turnover: Peptide synthesis requires raw materials like protected amino acids and resins. Efficient inventory management minimizes cash tied up in stock.
- •Capital expenditure impact: While capex is not part of CFO, it often precedes periods of high operational cash generation when new capacity comes online. For example, Bachem’s expansion in Vista, California, started in 2019 and likely contributed to higher depreciation, a non cash charge that reduces net income but not CFO.
Bachem (BCHMY) Cash From Operations TTM: Financial Health of a Peptide CDMO
On May 13, 2026, Zacks Investment Research published a report highlighting the cash from operations for the trailing twelve months (TTM) for Bachem Holding AG, traded as an unsponsored American Depositary Receipt (ADR) under the ticker BCHMY. While the metric itself is a standard financial figure, its context within the specialized contract development and manufacturing organization (CDMO) sector offers insights into the operational efficiency of a company that supplies critical building blocks for peptide-based therapeutics and research tools.
Peptides are short chains of amino acids that serve as hormones, signaling molecules, and drug candidates. Their production requires sophisticated chemical synthesis, purification, and quality control. Bachem, headquartered in Bubendorf, Switzerland, has been a major player in this niche since its founding in 1971, providing custom peptide synthesis, process development, and commercial manufacturing to pharmaceutical companies, biotech firms, and academic researchers.
The Zacks report focuses on cash from operations (CFO) over a rolling twelve-month window, a key indicator of how much cash a company generates from its core business activities. For a CDMO like Bachem, this metric reflects not only sales revenue but also the efficiency of its manufacturing operations, the management of receivables and payables, and the sustainability of its business model.
The Zacks Investment Research Coverage
Zacks Investment Research is a well known provider of financial data, analysis, and ratings, catering to individual and institutional investors. Its report on BCHMY’s cash from operations TTM is part of a regular series that tracks operational performance for publicly traded companies. The publication timestamp of May 13, 2026, indicates that the data covers the period ending on or around March 31, 2026, assuming a typical fiscal calendar.
Zacks calculates cash from operations using standardized definitions that align with generally accepted accounting principles (GAAP). The TTM figure aggregates four consecutive quarters of net income adjusted for non cash items such as depreciation, amortization, changes in working capital, and deferred taxes. This approach smooths out seasonal variations and provides a more current picture than a single fiscal year.
For Bachem, the TTM metric is particularly relevant because the company’s manufacturing capacity expansions and long term supply agreements affect working capital cycles. A strong CFO can support investments in new production lines, such as the large scale peptide synthesis facilities Bachem has built in the United States and Europe over the past decade.
Understanding Bachem and Its BCHMY ADR Structure
Bachem Holding AG is a Swiss corporation whose shares trade on the SIX Swiss Exchange. For investors outside Switzerland, an unsponsored ADR program, identified by the ticker BCHMY, allows trading of the company’s shares in the U.S. over the counter (OTC) market. An unsponsored ADR means that Bachem itself did not initiate the facility; instead, a depositary bank (commonly JPMorgan or Bank of New York Mellon) created the ADR to meet demand from American investors.
The ADR represents a specific number of underlying Swiss shares. Holders of BCHMY have indirect economic exposure to Bachem’s performance but may have limited voting rights or dividend access compared to direct share owners. The existence of the unsponsored ADR reflects significant interest from U.S. based investors in the peptide CDMO sector.
Bachem’s core business involves manufacturing peptides for clinical trials and commercial drugs. The company also produces custom peptides for research, including those used in immunology, oncology, and metabolic studies. Its client list includes many of the top 20 global pharmaceutical firms. The financial health of Bachem, as inferred from cash from operations, affects its ability to maintain rigorous quality standards, invest in new technologies like solid phase peptide synthesis automation, and respond to surges in demand.
Cash From Operations TTM as a Metric for a CDMO
Cash from operations TTM measures the cash generated by a company’s normal business activities over the past twelve months. It excludes cash from investing activities (like purchasing equipment) and financing activities (like issuing stock or borrowing). For Bachem, CFO is influenced by several factors:
- Revenue growth: Increased orders for peptide manufacturing translate directly into higher cash inflows, but timing depends on contract milestones and payment terms.
- Receivables management: Bachem often invoices after delivering batches. Longer payment cycles from large pharma clients can tie up cash, reducing CFO.
- Inventory turnover: Peptide synthesis requires raw materials like protected amino acids and resins. Efficient inventory management minimizes cash tied up in stock.
- Capital expenditure impact: While capex is not part of CFO, it often precedes periods of high operational cash generation when new capacity comes online. For example, Bachem’s expansion in Vista, California, started in 2019 and likely contributed to higher depreciation, a non cash charge that reduces net income but not CFO.
An investor tracking CFO TTM can assess whether Bachem is converting its reported earnings into actual cash. A declining CFO relative to net income might signal aggressive revenue recognition or deteriorating working capital terms. Conversely, rising CFO suggests strong operational discipline.
In the context of the Zacks report, the publication of this single metric indicates that analysts view it as a focal point for evaluating Bachem’s financial health. The company’s recent financial statements (e.g., annual report 2025) would show the underlying components. Historically, Bachem has reported healthy cash flows due to long term contracts with pharmaceutical partners for blockbuster peptide drugs like those in the GLP-1 receptor agonist class (e.g., semaglutide related analogs).
Broader Implications for the Peptide Industry
The cash from operations data for BCHMY matters beyond just investment circles. For researchers and biohackers who rely on peptide supply chains, the financial stability of a major CDMO like Bachem influences product availability, pricing, and innovation.
When a manufacturer has robust operational cash flow, it can maintain multiple synthesis platforms, stock rare building blocks, and invest in purification methods such as preparative HPLC. This ensures consistent quality for research grade peptides. Conversely, a cash constrained CDMO might cut corners, delay shipments, or reduce R&D spending.
Bachem’s financial performance also reflects the overall health of the peptide drug market. The growing adoption of peptide therapeutics for diabetes, obesity, cancer, and infectious diseases drives demand for manufacturing capacity. Strong CFO indicates that Bachem is capturing this demand effectively, which bodes well for the ecosystem of peptide suppliers and developers.
Zacks Investment Research likely selected the TTM metric to provide a timely snapshot. The report’s release on May 13, 2026, would encompass data from the second quarter of 2025 through the first quarter of 2026. This period captures any momentum from recent drug approvals or contract wins.
Frequently Asked Questions
Q: What does the BCHMY ticker represent, and how does it relate to Bachem Holding AG?
A: BCHMY is the ticker symbol for Bachem Holding AG’s unsponsored American Depositary Receipt (ADR). Each ADR represents a certain number of underlying Swiss shares, allowing U.S. investors to trade the company on the OTC market without direct involvement from Bachem. The ADR provides exposure to the company’s financial performance, including metrics like cash from operations.
Q: Why is cash from operations (TTM) important for evaluating a peptide CDMO?
A: Cash from operations TTM shows how much cash the company generates from its core manufacturing and service activities over the past twelve months. For a CDMO like Bachem, this metric reflects the efficiency of peptide synthesis operations, the ability to collect payments from clients, and the potential to reinvest in capacity expansion or R&D. It is a more concrete measure of financial health than earnings alone.
Q: How does Bachem’s financial performance affect researchers who buy custom peptides?
A: A financially stable Bachem is more likely to maintain reliable production schedules, invest in advanced purification technologies, and hold adequate raw material inventories. This translates into consistent quality, shorter lead times, and ongoing innovation in peptide synthesis methods. Researchers can trust that a CDMO with strong cash from operations will fulfill orders without disruption.
Q: What does “trailing twelve months” mean in the context of the Zacks report?
A: Trailing twelve months (TTM) refers to the most recent four consecutive quarters of financial data. For the report published on May 13, 2026, the TTM period would typically cover the second quarter of 2025 through the first quarter of 2026. This approach provides a current view of performance by aggregating the latest available data, smoothing out seasonal fluctuations.